Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Agios Pharmaceuticals, Inc. at current levels.
A rare disease franchise turning into a multi-indication PK activator platform, with sickle cell as the swing factor.
Where AGIO is headed
Agios is in the middle of converting a single approved drug for a vanishingly rare disease into a metabolic platform that treats several blood disorders, and the market is still pricing it like the former. PYRUKYND already has the PK deficiency franchise to itself, the thalassemia label expansion has opened a meaningfully larger commercial pool, and the RISE UP Phase 3 readout in sickle cell is the event that decides whether this is a $1.7B niche story or a $4-6B specialty hematology business by 2028. Revenue is compounding triple digits off a tiny base because thalassemia is real and ramping, not because of accounting flattery.
Read the full Compass Direction on AGIO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $28.14).
See the full AGIO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Agios Pharmaceuticals, Inc. at current levels. A rare disease franchise turning into a multi-indication PK activator platform, with sickle cell as the swing factor.
What is AGIO's Compass Score?
Agios Pharmaceuticals, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for AGIO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AGIO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.